Jane Street Group LLC Increases Stock Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Jane Street Group LLC lifted its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 29.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,359 shares of the company’s stock after acquiring an additional 17,410 shares during the period. Jane Street Group LLC’s holdings in SI-BONE were worth $1,081,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SIBN. FMR LLC grew its position in shares of SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of SI-BONE during the second quarter worth approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of SI-BONE by 24.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after acquiring an additional 2,108 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of SI-BONE by 9.0% during the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after purchasing an additional 903 shares during the period. Finally, Walleye Capital LLC acquired a new stake in shares of SI-BONE during the third quarter worth $144,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SI-BONE Price Performance

SI-BONE stock opened at $13.71 on Tuesday. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $21.64. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The business has a fifty day moving average of $13.46 and a two-hundred day moving average of $14.09. The company has a market cap of $574.97 million, a P/E ratio of -14.90 and a beta of 1.20.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SIBN shares. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of SI-BONE in a report on Wednesday, November 20th. Truist Financial increased their price target on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

Insider Buying and Selling at SI-BONE

In related news, insider Anthony J. Recupero sold 3,305 shares of SI-BONE stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total transaction of $44,881.90. Following the completion of the sale, the insider now owns 233,412 shares in the company, valued at approximately $3,169,734.96. This trade represents a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Laura Francis sold 10,048 shares of SI-BONE stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.58, for a total value of $126,403.84. Following the completion of the sale, the chief executive officer now owns 482,875 shares of the company’s stock, valued at $6,074,567.50. This trade represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,679 shares of company stock valued at $276,439. 3.90% of the stock is owned by company insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.